Understanding that communication and transparency from experts are critical enablers for widespread confidence in AI is the ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...

US Senators Bernie Sanders and Angus King have introduced a bill that seeks to ban direct-to-consumer (DTC) advertising by ...

Grail is preparing to file for FDA approval of its Galleri test for detecting multiple cancers from a single blood test after ...

The FDA has launched a review of clinical trials that plan to send American citizens' living cells to 'hostile' countries – ...

BIO 2025 this year came at a uniquely fraught moment for vaccination in the United States just days after HHS Secretary ...

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ...

Skyclarys is an important growth product for Biogen, which has been hit in the last few years by a series of pipeline ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

Gilead is now waiting for regulatory decisions on the twice-yearly PrEP in Europe and other markets, including South Africa ...

Cost and compliance may be colliding but, with the right strategy, organisations can navigate this intersection effectively.